title: The next steps in next-gen sequencing of cancer genomes.
abstract: The necessary infrastructure to carry out genomics-driven oncology is now widely available and has resulted in the exponential increase in characterized cancer genomes. While a subset of genomic alterations is clinically actionable, the majority of somatic events remain classified as variants of unknown significance and will require functional characterization. A careful cataloging of the genomic alterations and their response to therapeutic intervention should allow the compilation of an "actionability atlas" and the creation of a genomic taxonomy stratified by tumor type and oncogenic pathway activation. The next phase of genomic medicine will therefore require talented bioinformaticians, genomic navigators, and multidisciplinary approaches to decode complex cancer genomes and guide potential therapy. Equally important will be the ethical and interpretable return of results to practicing oncologists. Finally, the integration of genomics into clinical trials is likely to speed the development of predictive biomarkers of response to targeted therapy as well as define pathways to acquired resistance.
authors: D Neil
authors: DN
authors: Hayes
authors: William Y
authors: WY
authors: Kim
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor / Q000145:classification / Q000235:genetics*; D004273:DNA, Neoplasm / Q000235:genetics*; D015894:Genome, Human; D023281:Genomics / Q000379:methods / Q000639:trends; D059014:High-Throughput Nucleotide Sequencing / Q000379:methods / Q000639:trends; D006801:Humans
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm
references: Science. 2013 May 3;340(6132):626-30
references: 23558169
references: Cancer J. 2014 Mar-Apr;20(2):112-8
references: 24667955
references: Cell. 2013 Mar 28;153(1):17-37
references: 23540688
references: Ann N Y Acad Sci. 2010 Oct;1210:34-44
references: 20973797
references: Nat Rev Cancer. 2010 Feb;10(2):130-7
references: 20094047
references: J Natl Compr Canc Netw. 2010 Jul;8(7):740-801
references: 20679538
references: Sci Transl Med. 2014 Feb 19;6(224):224ra24
references: 24553385
references: Cancer Discov. 2012 Mar;2(3):214-26
references: 22585993
references: N Engl J Med. 2012 Feb 23;366(8):707-14
references: 22356324
references: Science. 2013 May 3;340(6132):622-6
references: 23558173
references: Nature. 2012 Mar 1;483(7387):100-3
references: 22281684
references: Nat Med. 2013 Sep;19(9):1098-100
references: 24013748
references: Blood. 2011 Nov 3;118(18):4817-28
references: 21849486
references: N Engl J Med. 2012 Jun 28;366(26):2443-54
references: 22658127
references: J Clin Oncol. 2014 May 1;32(13):1317-23
references: 24663044
references: Sci Transl Med. 2012 May 30;4(136):136ra68
references: 22649089
references: N Engl J Med. 2009 Feb 5;360(6):563-72
references: 19196673
references: Cancer Discov. 2011 Jun;1(1):44-53
references: 22586319
references: Ont Health Technol Assess Ser. 2010;10(24):1-48
references: 23074402
references: Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50
references: 20952405
references: Nature. 2014 Mar 20;507(7492):315-22
references: 24476821
references: Sci Transl Med. 2013 Mar 20;5(177):177ra38
references: 23515080
references: J Clin Oncol. 2009 Feb 10;27(5):663-71
references: 19114683
references: Nat Rev Cancer. 2012 May;12(5):349-61
references: 22475929
references: N Engl J Med. 2012 Mar 8;366(10):883-92
references: 22397650
references: J Clin Oncol. 2013 Mar 1;31(7):836-7
references: 23341523
references: N Engl J Med. 2009 Jul 9;361(2):123-34
references: 19553641
references: N Engl J Med. 2001 Apr 5;344(14):1031-7
references: 11287972
references: N Engl J Med. 2012 Jul 12;367(2):107-14
references: 22663011
references: Clin Pharmacol Ther. 2009 Jul;86(1):97-100
references: 19440188
references: Blood. 2014 Jul 17;124(3):453-62
references: 24891321
references: Nat Rev Cancer. 2007 Mar;7(3):169-81
references: 17318210
references: Science. 2004 Jun 4;304(5676):1497-500
references: 15118125
references: Cancer Cell. 2014 Jun 16;25(6):719-34
references: 24856586
references: Clin Cancer Res. 2013 Feb 1;19(3):657-67
references: 23251002
references: Annu Rev Immunol. 2014;32:189-225
references: 24423116
references: N Engl J Med. 2004 May 20;350(21):2129-39
references: 15118073
references: Nat Rev Cancer. 2009 Jan;9(1):28-39
references: 19104514
references: Cancer Cell. 2011 Jul 12;20(1):53-65
references: 21741596
references: Blood. 2014 Apr 24;123(17):2625-35
references: 24578504
references: J Clin Oncol. 2009 Feb 10;27(5):672-80
references: 19114685
references: N Engl J Med. 2001 Apr 5;344(14):1038-42
references: 11287973
references: J Clin Oncol. 2013 Nov 10;31(32):e439-42
references: 24043743
references: Nature. 2013 Oct 17;502(7471):333-9
references: 24132290
references: J Natl Compr Canc Netw. 2013 Feb 1;11(2):141-52; quiz 152
references: 23411381
references: Clin Cancer Res. 2014 Jul 15;20(14):3818-29
references: 24916698
references: Nat Rev Clin Oncol. 2009 Sep;6(9):519-27
references: 19636327
references: Sci Transl Med. 2011 Mar 23;3(75):75ra26
references: 21430269
references: BMJ. 1999 May 15;318(7194):1349
references: 10323827
references: Cancer Cell. 2014 Feb 10;25(2):152-65
references: 24525232
references: Nature. 2013 May 2;497(7447):108-12
references: 23563269
references: N Engl J Med. 2010 Jul 29;363(5):411-22
references: 20818862
references: Cancer Cell. 2011 Jul 12;20(1):66-78
references: 21741597
references: Nat Med. 2014 May;20(5):548-54
references: 24705333
references: Nat Rev Clin Oncol. 2014 Sep;11(9):509-24
references: 25001465
references: Nature. 2012 Jul 19;487(7407):330-7
references: 22810696
references: N Engl J Med. 2012 Jun 28;366(26):2455-65
references: 22658128
references: Nat Rev Cancer. 2012 May;12(5):323-34
references: 22513401
references: Cancer Cell. 2012 Mar 20;21(3):309-22
references: 22439926
references: J Clin Oncol. 2004 Dec 15;22(24):4991-5004
references: 15611513